Roth’s research interests focus on advancing novel synthetic methods and technologies for the generation of compound screening libraries.
Dr. Roth earned his Ph.D. in Chemistry at Colorado State University in 1988.
View All Publications
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA
BMC Biol. 2010;8:153
Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies.
Gardell SJ, Roth GP, Kelly DP
J Cardiovasc Transl Res. 2010 Oct;3(5):431-7
Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.
Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, Roth GP
J Med Chem. 2010 Jun 24;53(12):4793-7
Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C.
Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC
ACS Chem Biol. 2010 Mar 19;5(3):287-99
Isolation, synthesis, and biological activity of aphrocallistin, an adenine-substituted bromotyramine metabolite from the Hexactinellida sponge Aphrocallistes beatrix.
Wright AE, Roth GP, Hoffman JK, Divlianska DB, Pechter D, Sennett SH, Guzmán EA, Linley P, McCarthy PJ, Pitts TP, Pomponi SA, Reed JK
J Nat Prod. 2009 Jun;72(6):1178-83
Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN, Bentzien J, White A, Nemoto PA, Wang J, Man CC, Soleymanzadeh F, Khine HH, Kashem MA, Kugler SZ, Wolak JP, Roth GP, De Lombaert S, Pullen SS, Takahashi H
Bioorg Med Chem Lett. 2009 Feb 1;19(3):773-7
5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP, Robinson DJ, Khine HH, Pullen SS, Woska JR, Raymond EL, Sellati R, Cywin CL, Snow RJ, Kashem MA, Wolak JP, King J, Kaplita PV, Liu LH, Farrell TM, DesJarlais R, Roth GP, Takahashi H, Moriarty KJ
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5541-4
Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ, Winters M, Qiao L, Ryan D, DesJarlis R, Robinson D, Cook BN, Kashem MA, Kaplita PV, Liu LH, Farrell TM, Khine HH, King J, Pullen SS, Roth GP, Magolda R, Takahashi H
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5537-40
Gregory Roth's Research Focus
Cancer, Cardiovascular Diseases, Inflammatory/Autoimmune Disease, Metabolic Diseases, Aging-Related Diseases, Neurodegenerative and Neuromuscular Diseases
Gregory P. Roth, Ph.D., Associate Professor and Director of Medicinal Chemistry at Sanford-Burnham Medical Research Institute at Lake Nona, has 23 years of post-graduate pharmaceutical industry leadership experience and scientific accomplishments in the areas of Process Research, Combinatorial Chemistry and Medicinal Chemistry. Dr. Roth’s research interests focus on advancing novel synthetic methods and technologies for the generation of compound screening libraries based on natural product motifs.
Dr. Roth’s current work centers on the discovery of new chemical 'tools' in the areas of chemical biology and medicinal chemistry designed to answer significant biochemical questions in disease areas of unmet medical need. Currently, Dr. Roth’s lab is identifying and exploring the synthesis of enhanced analogs of several newly discovered natural product molecules which demonstrate properties that may be beneficial to the treatment of specific cancer types.
About Gregory Roth
Gregory P. Roth, Ph.D., holds 16 patents awarded or pending and has authored more than 60 research papers. Dr. Roth earned graduate degree in Chemistry at Colorado State University in 1988 under the direction of the late Professor A.I. Meyers. Dr. Roth also holds a Bachelor of Science (1979) and a Master of Science (1984) in Chemistry achieved at the State University of New York College at Fredonia in 1984. Prior to joining Sanford-Burnham in 2007 as an academic research investigator, Dr. Roth had over 20 years of pharmaceutical industry leadership and has contributed to drug discovery and development research programs at Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals and the Abbott Bioresearch Center. He is also a co-founder of Electra Pharmaceuticals, an emerging biotechnology company that is advancing natural products as therapeutics in the area of neurodegenerative disease.
Doctorate of Philosophy in Chemistry; Colorado State University; June 1984-September 1988
Advisor: Albert I. Meyers, Ph.D.
Dissertation Title: Asymmetric Tandem Additions to Naphthyloxazolines: Methods and Applications.
Master of Science in Chemistry; State University of New York at Fredonia; August 1982-May 1984.
Advisor: James R. Bowser, Ph.D.
Thesis Title: Directed Metallation Studies of 1,3-Bis(imidazolidinyl)benzene.
Bachelor of Science in Chemistry and Biology; State University of New York at Fredonia; August 1976-May 1979
Undergraduate Research Advisor: Thomas D. Harris, Ph.D.
co-Founder and Scientific Advisory Board Member, June 2010 to present
University of Florida-Gainesville
Adjunct Associate Professor, Medicinal Chemistry-College of Pharmacy, September 2010 to present
Orlando Museum of Art (OMA) 'Art's the Spark'
Advisory Committe Member, May 2011-Present
Boston University, Department of Chemistry and NIH Center for Methodology and Library Development
NIH-CMLD Scientific Advisory Board Member and Consultant, August 2002-August 2009
Adjunct Professor of Chemistry, September 2000-March 2007
American Chemical Society
Orlando Section Chair, January 2010-December 2010
Orlando Section Chair-Elect, January 2009-December 2009
H. Lee Moffitt Cancer Center
External Advisory Board Member (NIH P01 Drug Discovery Program), January 2009 to January 2011